Enlivex Ltd Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.31 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.42Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $8.4M Enterprise Value $6.5M Shares Outstanding 17.5M diluted Moat Rating None All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Enlivex Therapeutics Ltd. presents a unique, high-upside dual-strategy investment case. The company combines a clinical-stage biotechnology pipeline—centered on Allocetra™, an off-the-shelf macrophage reprogramming cell therapy targeting moderate-to-severe knee osteoarthritis—with a massive digital asset treasury. Enlivex holds approximately 79.57 billion RAIN tokens, the governance and utility token of the decentralized Rain prediction markets protocol, valued at approximately $1.16 billion as of late May 2026. This treasury value vastly exceeds the company's micro-cap equity valuation, offering a highly asymmetric risk-reward profile. While clinical development and cryptocurrency volatility present substantial risks, the deep discount of the equity relative to its liquid and option-backed treasury assets provides a compelling margin of safety for risk-tolerant investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$300.00 Mean target$300.00 High · most bullish analyst$300.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.0020% The bear case materializes if Allocetra™ fails to show statistically significant efficacy in the Phase IIb trial, or if safety concerns emerge. Simultaneously, severe regulatory crackdowns on decentralized prediction markets or proven on-chain manipulation allegations against the Rain protocol lead to a collapse in the RAIN token price and liquidity flight from exchanges like HTX and Kraken. The company is unable to regain the $1.00 Nasdaq minimum bid price, leading to delisting to the OTC markets, while the Lind convertible note covenants restrict financial flexibility. Base CaseCentral scenario $13.0050% In the base case, Enlivex successfully advances its Phase IIb trial of Allocetra™ in knee osteoarthritis across U.S. and European sites, maintaining its favorable safety and efficacy profile. The RAIN token treasury remains highly valuable, fluctuating with the broader crypto and prediction market cycles but anchoring the company's balance sheet. Enlivex utilizes its $20 million share repurchase program and strategic treasury management to regain compliance with the Nasdaq minimum bid price requirement, while the $21 million convertible debt facility provides sufficient runway to fund clinical operations through 2027. Bull CaseUpside scenario $20.0030% The bull case is driven by the successful execution of both clinical and digital asset strategies. Allocetra™ demonstrates strong, durable efficacy in its Phase IIb trial for knee osteoarthritis, paving the way for a lucrative partnership or rapid path to approval in a multi-billion dollar market. Concurrently, the Rain prediction markets protocol experiences explosive growth during major global events like the FIFA World Cup, driving massive token burns and pushing the value of Enlivex's RAIN holdings and its $2.23 billion intrinsic value option to new heights. The market re-rates ENLV to reflect its massive asset backing, and the company successfully regains Nasdaq compliance without dilution. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |